Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 2/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058633 | 0.89 | TP53 (0.39) | LMNAPOLBTP53ALDH1A1MEN1 | |
| SCHEMBL3058392 | 0.86 | SMN1; SMN2 (0.45) | LMNAPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL3064525 | 0.83 | SMN1; SMN2 (0.42) | LMNAPOLBALDH1A1KMT2AHPGD | |
| SCHEMBL3054778 | 0.82 | MAPT (0.49) | LMNAPOLBTP53ALDH1A1MEN1 | |
| SCHEMBL3053688 | 0.82 | ACHE (0.46) | LMNAPOLBTP53ALDH1A1MAPK1 | |
| SCHEMBL3066650 | 0.81 | KMT2A (0.46) | LMNAPOLBALDH1A1KMT2AHPGD | |
| SCHEMBL3060136 | 0.81 | MAPT (0.43) | LMNAPOLBALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3051045 | 0.81 | SCN9A (0.45) | LMNAALDH1A1KMT2AHPGDMAPK1 | |
| SCHEMBL3054766 | 0.80 | POLB (0.40) | LMNAPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL3063971 | 0.79 | MCL1 (0.41) | LMNAALDH1A1MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | LMNA 1113/4885POLB 3933/4885TP53 4360/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | LMNA 1113/4885POLB 3933/4885TP53 4360/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | LMNA 1113/4885POLB 3933/4885TP53 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.